| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5614525 | Journal of Cardiology | 2017 | 6 Pages |
Abstract
It is feasible to treat AMI patients with prasugrel. HTPR is a significant independent risk factor for adverse events in AMI patients receiving prasugrel after primary PCI.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Tetsuya MD, PhD, FJCC, Yusuke MD, Yuya MD, Masamichi MD, PhD, Soichiro MD, PhD, Akihisa MD, PhD, Hironori MD, PhD, FJCC,